Transcription of Guideline on the clinical development of medicinal ...
{{id}} {{{paragraph}}}
Example: stock market
Guideline on the clinical development of medicinal ...
30 Churchill Place Canary Wharf London E14 5EU United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged. 15 December 2016 EMA/CHMP/970057/2011 Committee for medicinal Products for Human Use (CHMP) Guideline on the clinical development of medicinal products intended for the treatment of pain Draft Agreed by Biostatistics Working Party December 2012 Draft Agreed by Paediatric Committee March 2013 Draft Agreed by Central Nervous System Working Party May 2013 Adoption by CHMP for release for consultation 30 May 2013 Start of public consultation 1 June 2013 End of consultation (deadline for comments) 30 November 2013 Draft Agreed by
Chronic pain is generally regarded as maladaptive, with lack of survival value to the organism. In addition to somatic and psychological factors, genetic5,6,7, environmental or socioeconomic factors may also contribute to the risk of developing chronic pain. Chronic pain
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: